

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Yuichiro AMANO et al.

Serial No. 10/521,174

Filed January 14, 2005



Mail Stop: PCT

Attorney Docket No. 2005\_0041A

DISEASE MODEL ANIMAL CARRYING  
HETEROLOGOUS PPAR ALPHA GENE  
INTRODUCED THEREINTO AND USE THEREOF  
[Corresponding to PCT/JP03/08921  
Filed July 14, 2003]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☐ each U.S. Patent and U.S. Patent application publication;
- ☒ each reference previously cited in the international application PCT/JP03/08921; and/or
- ☐ each reference previously cited in prior parent application Serial No. \_\_\_\_\_.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and**

**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Yuichiro AMANO et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
August 26, 2005

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: August 26, 2005

ATTY DOCKET NO.  
2005\_0041ASERIAL NO.  
10/521,174APPLICANT  
Yuichiro AMANO et al.FILING DATE  
January 14, 2005

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AD	02/47478	6/2002	WO				
	AC	95/11974	5/1995	WO				
	AF	02/064632	8/2002	WO				
	AG	2002-306021	10/2002	JP			Abstract	
	AH							

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI	T. Sher et al., "cDNA Cloning, Chromosomal Mapping, and Functional Characterization of the Human Peroxisome Proliferator Activated Receptor", Biochemistry, Vol. 32, No. 21, pp. 5598-5604, June 1993.
	AJ	R. Mukherjee et al., "Human and Rat Peroxisome Proliferator Activated Receptors (PPARs) Demonstrate Similar Tissue Distribution but Different Responsiveness to PPAR Activators", J. Steroid Biochem. Mol. Biol., Vol. 51, No. 3/4, pp. 157-166, November 1994.
	AK	Journal of the Japan Diabetes Society, 45, (Sup. 2): S-169, II-D-28, 2002, which is the abstracts of the 45 <sup>th</sup> Annual Meeting of the Japan Diabetes Society, published on April 15, 2002.
	AL	Diabetes, 51, (Sup. 2): A31, 127-OR, which is the abstract book of 62 <sup>nd</sup> Scientific Sessions of the American Diabetes Association, published in June 2002.
	AM	J.C. Fruchart et al., "The Role of Fibric Acids in Atherosclerosis", Current Atherosclerosis Reports, Vol. 3, No. 1, pp. 83-92, 2001.
	AN	A. Tabernero et al., "Activation of the peroxisome proliferator-activated receptor $\alpha$ protects against myocardial ischaemic injury and improves endothelial vasodilation", BMC Pharmacology, Vol. 2, No. 10, pp. 1-10, April 2002.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.